CLINICAL DATA

20+ years of clinical validation.
200 research collaborations. 100s of publications.


Funding for future clinical research and innovation.

We’re thrilled to have received funding of €4 million from Horizon 2020, the biggest research and innovation program in the European Union. Donated in June 2015, under grant agreement no 672570, our gift from Horizon 2020 is being used to fund a three-year project whose goal is to achieve final evidence for the clinical utility of MammaPrint®.


Our overall objective is to meet the reimbursement requirements in each targeted market and thereby gain comprehensive uptake by international clinical guideline committees and reimbursement bodies. As a result, many more breast cancer patients will potentially have access to the MammaPrint test. The MoTriColor study, part of the Horizon 2020 grant, is for the development of colon cancer subtypes. Further information can be viewed at motricolor.eu.

About Horizon 2020

Horizon 2020 believes that research is an investment, and is offering different companies and institutions almost €80 billion worth of grants from 2014 to 2020 – that’s in addition to the private investment that this money will attract. The program supports research projects in developing world-class science and innovation, making it easier for public and private sectors to work together. The aim is to enable more breakthroughs, discoveries, and world-firsts by taking great ideas from the lab to the market.

Primary Project Objectives

  • Gather additional clinical evidence on the prognostic value (the likely course of breast cancer in an endocrine therapy-treated individual) of MammaPrint (work package 2 – ABCSG 8 trial)
  • Obtain additional clinical evidence on the predictive value (identify sub-populations of patients who are most likely to respond to a given therapy) of MammaPrint (work package 3 – STO high risk trial)
  • Collect additional clinical evidence on the clinical utility (the likelihood that the test will, by prompting an intervention, result in an improved health outcome) of MammaPrint (work package 3 – STO high risk trial)

  • Demonstrate adherence to the test results in breast cancer patients (work package 5 – PRospective study to measure the Impact of MammaPrint on adjuvant treatment [PRIMe])

  • Determine required preconditions for full scale adoption in European and North American markets (work package 6 – communication and dissemination)